Overview


According to FutureWise analysis, the artificial coma-medically induced coma market is expected to reach US$0.91 billion by 2031 at a CAGR of 3.30%. This growth is mainly driven by the rising occurrence of traumatic brain injuries, severe neurological conditions, and complex surgical procedures that require neuroprotective interventions. The market is further supported by the increasing acknowledgment of medically induced comas as an essential therapeutic approach for reducing intracranial pressure and facilitating brain tissue recovery in intensive care settings.

FutureWise Market Research has released a report that provides an in-depth analysis of Artificial Coma/Medically Induced Coma Market trends that will impact the overall market growth. Furthermore, it includes detailed information on the profitability graph, SWOT analysis, market share, and regional expansion of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to a research study conducted by FutureWise research analysts, the Artificial Coma/Medically Induced Coma Market is expected to experience substantial growth by the end of the forecast period. The report predicts that this business is expected to register a notable growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Astrazeneca Plc.
  • B. Braun Melsungen
  • Baxter Healthcare Corporation
  • Dr.Reddy's Laboratories
  • Fresenious SECo.
  • Hikma Pharmaceuticals
  • Pfizer Inc.
  • Piramal Healthcare
  • Teva Pharmaceuticals Industries Ltd.
  • Viatris Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Artificial Coma-Medically Induced Coma Market:

B. Braun Melsungen

  • There is ongoing activity in product and infusion therapy. The company reported sales growth for fiscal year 2024 and has been active in supplying infusion/IV fluids and updating infusion pumps, which include regulatory communications regarding some pump corrections and planned recalls for 2024–2025.

Baxter Healthcare Corporation

  • Baxter, a major supplier of infusion pumps and IV products, faced early alerts and recalls from the FDA in 2025. As a result, the company suspended shipments of some Novum and Novum-IQ pumps after reports of injuries. Baxter has since updated the usage instructions and communicated the necessary corrections. These developments have financial and market implications for infusion pumps used to deliver sedation and ICU medications.

Fresenius SECo.

  • Recognized as a leading player in artificial coma support, Fresenius is noted for supplying drugs and ICU consumables, including anesthesia, sedation, and ICU fluids.

By Drug Type

  • Propofol
  • Barbiturate

By Application

  • Status Epilepticus
  • Stroke
  • Traumatic Brain Injury
  • Brain Infections
  • Drug Overdose
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Artificial Coma/Medically Induced Coma Market By Drug Type, By Application, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Artificial Coma-Medically Induced Coma Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Artificial Coma/Medically Induced Coma Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Artificial Coma-Medically Induced Coma Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.   Artificial Coma-Medically Induced Coma Market, By Drug Type Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Propofol
        2. Barbiturate

  • 8.   Artificial Coma-Medically Induced Coma Market, By Application Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Status Epilepticus
        2. Stroke
        3. Traumatic Brain Injury
        4. Brain Infections
        5. Drug Overdose
        6. Others

  • 9.   Artificial Coma-Medically Induced Coma Market, By Distribution Channel Historical Analysis and Forecast 2025-2033 (USD Million)
    •   1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies

  • 10.   North America Artificial Coma-Medically Induced Coma Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2025-2033

  • 11.   Latin America Artificial Coma-Medically Induced Coma Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2025-2033

  • 12.   Europe Artificial Coma-Medically Induced Coma Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 13.   Asia Pacific Artificial Coma-Medically Induced Coma Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2025-2033

  • 14.   Middle East and Africa Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2025-2033

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AstraZeneca Plc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. B. Braun Melsungen
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Baxter Healthcare Corporation
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Dr.Reddy's Laboratories
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Fresenious SECo.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Hikma Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Pfizer Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Piramal Healthcare
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Teva Pharmaceuticals Industries Ltd.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Viatris Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Osteosarcoma Market

Read More

Fibrosarcoma Market

Read More
Partner

Our Clients